Develops TGFB2-targeting therapeutics for cancer and other serious diseases and advances programs via partnership and joint-venture model to accelerate development and manage clinical risk for patients and investors. Combines ultra-small molecular nanomedicine for deep tissue penetration and improved pharmacology with an AI-driven evidence interrogation platform for biomarker discovery and translational insight.